Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
OctoPlus N.V. (AMS:OCTO) OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO), the drug delivery company, announces today that its Annual General Meeting of Shareholders (the "Meeting") has appointed the new Executive Board and adopted a change in the composition of the Supervisory Board of Directors.
On 16 October, OctoPlus announced that the Board of Supervisory Directors proposed to expand the Executive Board with two new members. The new Board would consist of Chief Executive Officer, Simon Sturge, Joost Holthuis, current CEO and founder, who would take up the new position of Chief Operating Officer, Chief Financial Officer Hans Pauli and Chief Business Officer Gerben Moolhuizen.
Expansion of the Executive Board to four members and the new division of responsibilities will ensure optimal use of expertise and experience to guide the Company to the next level and position OctoPlus for future growth and the building of shareholder value.
During today's Meeting the shareholders approved the appointment of Mr. Sturge and Mr. Moolhuizen as members of the Executive Board.
As a consequence of these appointments, the Executive Board is composed as follows: 1. Mr. S.J. Sturge (Chief Executive Officer) 2. Mr. J.J.M. Holthuis (Chief Operating Officer) 3. Mr. J.C.H.L. Pauli (Chief Financial Officer) 4. Mr. G. Moolhuizen (Chief Business Officer)
During today's Annual General Meeting of Shareholders, the reappointment of Mr. Kuijten and the appointment of Mr. Eelkman Rooda were approved.
As a consequence of this appointment and re-appointment, the Board of Supervisory Directors is composed as follows: 1. Mr. J. Stellingsma (chairman) 2. Mr. Ph.L. Smith 3. Mr. R.R. Kuijten 4. Mr. P.H.M. Toon 5. Mr. F. Eelkman Rooda
All other agenda items of today's Meeting were also approved by the shareholders.
For further information, please contact: Rianne Roukema, Corporate Communications, telephone number +31 (71) 524 1071 or e-mail IR@octoplus.nl.
About OctoPlus OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.
Our pipeline consists of 4 products in pre-clinical and clinical development. The lead product incorporating our technology is Locteron, a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, which has been licensed to Biolex Therapeutics and is being manufactured by OctoPlus. Locteron is currently in Phase II clinical studies. Furthermore, our pipeline comprises a product candidate for the treatment of chronic middle ear infection, which has completed Phase II clinical proof of concept, and two pre-clinical-stage single-shot vaccines.
In addition, OctoPlus is a European leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
